CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹-31 Cr | ₹82 Cr | ₹184 Cr | ₹622 Cr | ₹1,660 Cr |
What is the latest Total Non-Current Liabilities ratio of CIPLA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹-31 Cr |
| Mar2024 | ₹82 Cr |
| Mar2023 | ₹184 Cr |
| Mar2022 | ₹622 Cr |
| Mar2021 | ₹1,660 Cr |
How is Total Non-Current Liabilities of CIPLA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹-31 Cr | Negative | |
| Mar2024 | ₹82 Cr | -55.36 | |
| Mar2023 | ₹184 Cr | -70.48 | |
| Mar2022 | ₹622 Cr | -62.55 | |
| Mar2021 | ₹1,660 Cr | - | |
Compare Total Non-Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹104,589.9 Cr | 5.4% | 3.1% | -13.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹388,680.0 Cr | -2.9% | -8.9% | -3.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹168,817.0 Cr | 1.2% | 4.2% | 8.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹139,297.0 Cr | -1.7% | -3.6% | 27.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,828.0 Cr | 6.8% | 1.3% | 13.2% | Stock Analytics | |
| MANKIND PHARMA | ₹93,582.0 Cr | 5.8% | 13.4% | -11.3% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 5.4% |
3.1% |
-13.6% |
| SENSEX | -2.3% |
3.3% |
-2.4% |
You may also like the below Video Courses